Sam Brusco, Associate Editor05.01.24
Veranex, an integrated global service platform for the medtech industry, has acquired HORUS Scientific, a pathology and histology facility.
HORUS Scientific's Director, Dr. James 'Butch' Stanley, DVM, MS, DACVP, has developed and implemented histopathology protocols for over twenty years. Veranex said the acquisition solidifies global commitment by broadening end-to-end service capabilities for medtech innovation.
“HORUS is excited to join the Veranex team—an organization with an outstanding reputation," said Dr. Stanley. "We're eager to share our knowledge and expertise with industry leaders to provide enhanced access, flexibility, and services for medtech clients in North America and beyond."
Veranex offers product design and engineering, CRO (contract research organization) services, and market access and reimbursement consulting. The company also offers preclinical services, with capabilities from proof-of-concept studies through final Good Laboratory Practice (GLP) studies conducted for submission to regulatory agencies.
The company’s Atlanta and Paris Labs offer services for complex preclinical studies in large models of novel medical technologies, from early prototypes to devices for human trials. HORUS Scientific's North American capability complements Veranex's in-house pathology and histology services in Paris, fortifying the company’s pathology service line.
In December 2023, Veranex acquired T3 Labs, establishing its Atlanta-based preclinical laboratory.
HORUS Scientific's Director, Dr. James 'Butch' Stanley, DVM, MS, DACVP, has developed and implemented histopathology protocols for over twenty years. Veranex said the acquisition solidifies global commitment by broadening end-to-end service capabilities for medtech innovation.
“HORUS is excited to join the Veranex team—an organization with an outstanding reputation," said Dr. Stanley. "We're eager to share our knowledge and expertise with industry leaders to provide enhanced access, flexibility, and services for medtech clients in North America and beyond."
Veranex offers product design and engineering, CRO (contract research organization) services, and market access and reimbursement consulting. The company also offers preclinical services, with capabilities from proof-of-concept studies through final Good Laboratory Practice (GLP) studies conducted for submission to regulatory agencies.
The company’s Atlanta and Paris Labs offer services for complex preclinical studies in large models of novel medical technologies, from early prototypes to devices for human trials. HORUS Scientific's North American capability complements Veranex's in-house pathology and histology services in Paris, fortifying the company’s pathology service line.
In December 2023, Veranex acquired T3 Labs, establishing its Atlanta-based preclinical laboratory.